Literature DB >> 29392638

Long-term impact of dry eye symptoms on vision-related quality of life after phacoemulsification surgery.

Wenwen Xue1,2,3,4, Ming-Ming Zhu1,2,3,4, Bi-Jun Zhu1,2,3, Jian-Nan Huang1,2,3,4, Qian Sun1,2,3, Yu-Yu Miao1,2,3, Hai-Dong Zou5,6,7,8.   

Abstract

PURPOSE: To observe the long-term changes in dry eye symptoms and vision-related quality of life in age-related cataract patients after phacoemulsification.
METHODS: A total of 101 cataract patients after phacoemulsification combined with IOL implantation (Ph-IOL) in one eye were enrolled. Visual acuity, tear film breakup time (BUT), and Schirmer test 1 (ST1) were measured before and 1, 3, and 6 months after surgery. Ocular Surface Disease Index (OSDI) scores were used to evaluate the severity of dry eye symptoms. Utility values were assessed by the time trade-off (TTO), standard gamble for death (SGD), standard gamble for blindness (SGB) and rating scale (RS).
RESULTS: The average LogMAR visual acuity in the operated eye was 1.35 ± 0.50 and increased rapidly after Ph-IOL, approaching a peak at 3 months (0.26 ± 0.15). The BUT and ST1 results decreased abruptly 1 month after surgery and gradually recovered until 6 months. OSDI scores increased significantly after surgery and gradually decreased until 6 months. Utility values evaluated by TTO, SGD, SGB and RS before surgery were 0.67 ± 0.19, 0.75 ± 0.15, 0.67 ± 0.20 and 0.2 ± 0.18, respectively, and increased to 0.91 ± 0.06, 0.98 ± 0.04, 0.92 ± 0.52 and 0.91 ± 0.06, 6 months after. Utility values measured with TTO, SGB or RS correlated significantly (P < 0.05) with visual acuity and OSDI scores pre- and postoperatively.
CONCLUSIONS: Dry eye symptoms persist more than 3 months after Ph-IOL. Utility values were negatively influenced by dry eye symptoms.

Entities:  

Keywords:  Cataract; Dry eye; Phacoemulsification; Utility; Visual acuity

Mesh:

Year:  2018        PMID: 29392638     DOI: 10.1007/s10792-018-0828-z

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  8 in total

Review 1.  New approaches for diagnosis of dry eye disease.

Authors:  Abdelrahman M Elhusseiny; Ali A Khalil; Reem H El Sheikh; Mohammad A Bakr; Mohamed Gaber Eissa; Yasmine M El Sayed
Journal:  Int J Ophthalmol       Date:  2019-10-18       Impact factor: 1.779

2.  The Effect of Past Cataract Surgery within the Medium to Long-Term Period on Patients with Dry Eye Disease.

Authors:  Lei Siew; Louis Tong
Journal:  J Clin Med       Date:  2022-02-13       Impact factor: 4.241

3.  Evaluation of the Protective Effect of an Ophthalmic Viscosurgical Device on the Ocular Surface in Dry Eye Patients during Cataract Surgery.

Authors:  Do Yeh Yoon; Joo Hyun Kim; Hyun Sun Jeon; Hee Eun Jeon; Sang Beom Han; Joon Young Hyon
Journal:  Korean J Ophthalmol       Date:  2019-10

4.  Association among Blink Rate, Changes in Ocular Surface Temperature, Tear Film Stability, and Functional Visual Acuity in Patients after Cataract Surgery.

Authors:  Takashi Itokawa; Yukinobu Okajima; Takashi Suzuki; Tatsuhiko Kobayashi; Yuto Tei; Koji Kakisu; Yuichi Hori
Journal:  J Ophthalmol       Date:  2019-08-19       Impact factor: 1.909

Review 5.  Iatrogenic Dry Eye Disease: Dealing with the Conundrum of Post-Cataract Discomfort. A P.I.C.A.S.S.O. Board Narrative Review.

Authors:  Pasquale Aragona; Maurizio Rolando; Rita Mencucci; Roberto Vignapiano; Pierangela Rubino; Eleonora Favuzza; Emilia Cantera
Journal:  Ophthalmol Ther       Date:  2021-02-08

6.  Evaluation of Ocular Surface after Cataract Surgery-A Prospective Study.

Authors:  Agne Sidaraite; Lina Mikalauskiene; Andrzej Grzybowski; Reda Zemaitiene
Journal:  J Clin Med       Date:  2022-08-04       Impact factor: 4.964

7.  The assessment of the impact of glistening on visual performance in relation to tear film quality.

Authors:  Amanda Argay; Peter Vamosi
Journal:  PLoS One       Date:  2020-10-12       Impact factor: 3.240

8.  Trehalose/sodium hyaluronate eye drops in post-cataract ocular surface disorders.

Authors:  Carlo Cagini; Giovanni Torroni; Marco Mariniello; Giampiero Di Lascio; Gianluca Martone; Angelo Balestrazzi
Journal:  Int Ophthalmol       Date:  2021-05-06       Impact factor: 2.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.